Results 151 to 160 of about 25,024 (228)

Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system. [PDF]

Front Pharmacol
Chokkakula S, Guo Q, Zhang X, Bin Jumah J, Naveen B, Yang B.   +5 more
europepmc   +1 more source

Effect of the antidepressant drug paroxetine in downregulating the biofilm-adhering genes in Staphylococcus aureus: In vitro and in silico studies. [PDF]

Medicine (Baltimore)
AlKhalidi HM, Ali AH, Abo-Ouf AM, El-Bidawy MH, Arafah AMR, Aldawsari SM, Dayel SB, Hajelbashir MI, Abd El-Naem MM, AlGhamdi MAA, Alhumaid KH, Abd El-Lateef AES, Aljabr KHE, Khairy HA, Samhan MA.   +14 more
europepmc   +1 more source

Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial. [PDF]

Anesthesiology
Florian J, Keshishi D, Gershuny V, Salcedo P, van der Schrier R, Burkhart K, Shah A, Racz R, Patel V, DePalma R, Matta M, Vegesna G, Hsiao CH, Rouse R, Fein M, Stone M, Dahan A, Strauss DG.   +17 more
europepmc   +1 more source

Shared Decision Making on Methylphenidate in Hypertrophic Cardiomyopathy and ADHD in a Young Athlete. [PDF]

JACC Case Rep
Rechcińska A, Rechciński T.
europepmc   +1 more source

Pioneering a Hybrid Decentralized Clinical Trial in South Korea: Assessing Feasibility, Data Integrity, and Participant Perceptions. [PDF]

Clin Transl Sci
Kim E, Bae S, Huh KY, Lee S, Shin W, Yoo H, Gu N, Kim A.   +7 more
europepmc   +1 more source

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population. [PDF]

Pharmacogenomics J
Baye JF, Petry NJ, Hines L, Weaver M, Reinke M, Brady H, Massmann A, Schultz A.   +7 more
europepmc   +1 more source

Paroxetine as a Therapeutic Agent in Inflammatory Osteolysis: Mechanistic Insights and Efficacy. [PDF]

Drug Des Devel Ther
Huang J, Wang Z, Liu J, Zhang J, Deng K, Huang S, Zhou S.   +6 more
europepmc   +1 more source

Evaluating <i>Caenorhabditis elegans</i> as a Toxicity Model for Reuptake Inhibitors. [PDF]

MicroPubl Biol
Hernandez CE, Van Stone A, So C.
europepmc   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools. [PDF]

Clin Pharmacokinet
Huber RL, Scherf-Clavel O.
europepmc   +1 more source